CIK 0002035832 · <br>Emerging growth company
Aktis Oncology, Inc.
Sign in to watch- Ticker
- AKTS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 852584233
- Phone
- 978-237-4380
- Business address
- 17 DRYDOCK AVENUE, SUITE #17-401, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $258,621
- in 1 filing, $259K under 10b5-1 plans
Net −$258,621. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-12 | Foley Todd Director | Purchase | +232,870 | $18.00 | $4.2M | 4,235,403 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Purchase | +1,112,777 | $18.00 | $20.0M | 10,260,064 |
| 2026-01-12 | GADICKE ANSBERT 10% owner | Purchase | +1,112,777 | $18.00 | $20.0M | 10,260,064 |
| 2026-01-12 | Vida Ventures II, LLC 10% owner | Purchase | +812,455 | $18.00 | $14.6M | 5,671,825 |
| 2026-01-12 | Vida Ventures II, LLC 10% owner | Purchase | +22,545 | $18.00 | $406K | 157,387 |
| 2026-01-12 | Kim Helen Susan Director | Purchase | +812,455 | $18.00 | $14.6M | 5,671,825 |
| 2026-01-12 | Kim Helen Susan Director | Purchase | +22,545 | $18.00 | $406K | 157,387 |
| 2026-01-12 | EcoR1 Capital, LLC Director | Purchase | +2,077,779 | $18.00 | $37.4M | 4,348,658 |
| 2026-01-12 | EcoR1 Capital, LLC Director | Purchase | +144,443 | $18.00 | $2.6M | 347,305 |
Page 1 of 1 · 9 trades